Joel Randolph Hecht

11PUBLICATIONS
80CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 21, 2026
Amivantamab Monotherapy in Chemorefractory <i>RAS</i>/<i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

|Apr 01, 2026
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials.

J Randolph Hecht, Julian R Molina, Kirstin Liechty

|May 05, 2025
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.

Jean-Baptiste Bachet, Aimery de Gramont, Morteza Raeisi

|Mar 29, 2025
Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma.

Joel Randolph Hecht, Arjun Oberoi, Elena Garralda Cabanas

|Jan 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.

Jason J Luke, Randy F Sweis, J Randolph Hecht

|Jul 23, 2024
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.

Anwaar Saeed, Josep Tabernero, Aparna Parikh

Pageof 2

Frequent Collaborators

3 joint publications

Eric Van Cutsem

2 joint publications

Arun S Singh

2 joint publications

Bartosz Chmielowski

1 joint publications

Sara Lonardi